Sara Susca - Publications

Lichenoid drug eruption during treatment with brodalumab for psoriasis.

Journal: Italian journal of dermatology and venereology

Published: February 03, 2025

Drug Survival, Safety, and Effectiveness of Secukinumab for up to 5 Years in Patients with Psoriasis and Psoriatic Arthritis: A Long-Term Real-Life Experience.

Journal: Journal of personalized medicine

Published: June 07, 2024

Clinical characteristics and response to biological therapies for inverse psoriasis: a real-life comparison between the therapeutic effects of anti-IL-23 and anti-IL-17 agents.

Journal: International journal of dermatology

Published: January 14, 2024

Anti-IL23 in inflammatory bowel disease patients with dermatological indication: The shared gastroenterological-dermatological clinic experience.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: August 07, 2023

Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Published: July 12, 2023

Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real-life experience on 638 patients with psoriasis.

Journal: Experimental dermatology

Published: March 22, 2023

Oral doxycycline in HIV-related synchronous malignant syphilis and condyloma lata.

Journal: Italian journal of dermatology and venereology

Published: January 18, 2023

"Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors.

Journal: Experimental dermatology

Published: November 28, 2022

Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: November 21, 2022

Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents.

Journal: Clinical and experimental dermatology

Published: November 18, 2022

Brodalumab efficacy in bio-naïve psoriasis patients: real-life experience of 202 subjects up to 48 weeks.

Journal: The Journal of dermatological treatment

Published: September 14, 2022

Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement.

Journal: Dermatologic therapy

Published: July 22, 2022